A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Plaque Psoriasis

Interventions

DRUG

dalazatide

Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.

DRUG

placebo

placebo, Subcutaneous injection twice per week for a total of 9 doses

Trial Locations (1)

Innovaderm Research, Inc, Montreal